Last reviewed · How we verify
IBU BID
IBU BID is ibuprofen formulated for twice-daily dosing to provide sustained anti-inflammatory and analgesic effects.
IBU BID is ibuprofen formulated for twice-daily dosing to provide sustained anti-inflammatory and analgesic effects. Used for Mild to moderate pain, Inflammation and fever, Osteoarthritis or rheumatoid arthritis.
At a glance
| Generic name | IBU BID |
|---|---|
| Sponsor | Pfizer |
| Drug class | NSAID (nonsteroidal anti-inflammatory drug) |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thereby decreasing inflammation, pain, and fever. The BID (twice-daily) formulation is designed to optimize dosing frequency for patient compliance and maintain therapeutic drug levels throughout the day.
Approved indications
- Mild to moderate pain
- Inflammation and fever
- Osteoarthritis or rheumatoid arthritis
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Abdominal pain
- Headache
- Dizziness
- Rash
Key clinical trials
- ERAS (Enhanced Recovery After Surgery) and Multimodal Analgesia in Laparoscopic Cholecystectomy
- Selected Exercise Program on Upper Cross Syndrome Post-unilateral Mastectomy (NA)
- Helping Osteoarthritis Patients to Walk With NSAID (PHASE4)
- Postoperative Analgesic Efficacy of SPSIPB in Anterior Cervical Discectomy (NA)
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Psychosocial Factors and Postoperative Pain in Aesthetic Breast Surgery
- The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair (PHASE4)
- A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBU BID CI brief — competitive landscape report
- IBU BID updates RSS · CI watch RSS
- Pfizer portfolio CI